MedPath

Real-time monitoring the occurrence of gout flares in patients by incorporation of the 2017 gout flare definition into an eHealth platform: a feasibility study.

Completed
Conditions
gout
10037546
10023213
Registration Number
NL-OMON45981
Lead Sponsor
Sint Maartenskliniek
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

- Patients aged *18 years
- A diagnosis of crystal proven gout or a high clinical suspicion of gout
- At least one (possible) flare reported in the last three months
- Possession of an Android or iOS-based smartphone or tablet

Exclusion Criteria

- Stable gout with no flares over the last year
- Life expectancy less than 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameter will be the score provided by the System Usability<br /><br>Scale (SUS) [Brooke J. Usability Evaluation in Industry 1996] as a measure for<br /><br>*perceived ease of use*. The SUS is a ten item questionnaire with five response<br /><br>options, generating a score between zero and forty. This score is multiplied<br /><br>two and a half times to adjust the score to a zero and one hundred point score.<br /><br>Finally, this score is categorised in concordance with Bangor et al:<br /><br>Score = >80 Continue research on Q1.6 gout app without adjustments<br /><br>Score = 50 * 80 Adjust Q1.6 gout app before continuing<br /><br>Score = <50 Abolish or redesign platform applying gout flare<br /><br>measurement<br /><br><br /><br>The other main parameter is the *perceived usefulness*. This is a descriptive<br /><br>measure and assessed using the translated and adapted version of the<br /><br>questionnaire by Davis Jr.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>To be able to answer the secondary research questions, the following secondary<br /><br>study parameters will also be collected:<br /><br>- Number of gout flares reported by patients during three months<br /><br>- Proportion of gout flares reported by patients that last longer than three<br /><br>consecutive days.<br /><br>- Uptake: number of patients that have been approached to commit to the<br /><br>feasibility study in order to reach thirty inclusions<br /><br>- Period of use: the time period that the subject actively uses the app<br /><br>- Application adherence: percentage of days that questions have been answered<br /><br>- All contact with the Q1.6 helpdesk of included subjects will be documented<br /><br>using a case report form</p><br>
© Copyright 2025. All Rights Reserved by MedPath